Drug Delivery Technologies: Commercial Prospects 2013-2023
-
Upload
visiongain -
Category
Health & Medicine
-
view
179 -
download
3
Transcript of Drug Delivery Technologies: Commercial Prospects 2013-2023
©noticeThis material is copyright 2010 by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.
Drug Delivery Technologies: Commercial Prospects 2013-2023
www.visiongain.com
Contents
1.1 Drug Delivery Technology: Market Review
1.2 Aims, Scope and Format of Report
1.2.1 Chapter Outlines
1.3 Research and Analysis Methods
2.1 Introduction to Drug Delivery Technologies (DDT)
2.2 Types of Technologies for Drug Delivery
2.2.1 Sustained/Controlled Release Systems
2.2.2 Injection
2.2.3 Needle Free Injection
2.2.4 Pulmonary, Buccal and Nasal Delivery
2.2.5 Pills and Capsules
2.3 Biopharmaceuticals
2.3.1 Overview of the Biologicals Market
2.3.2 The Biological Drug Industry is Strong
2.4 Biotech Drugs with Associated Drug Delivery Technologies
2.4.1 Pegylated Interferons
2.4.2 Crowded Insulin Market Has Forced Investment in DDT
2.5 Exubera - Case Study for Alternative Biological Delivery Methods
2.5.1 The First Inhaled Insulin
2.5.2 Description and Development History
2.5.3 Generex and MannKind Developing Next-Generation Oral Insulins
2.5.4 Challenges Facing Afrezza and Oral-lyn
2.6 The Main Challenges for Biological Drug Delivery
2. Introduction
1. Executive Summary
www.visiongain.com
Contents
3.1 The World Drug Delivery Technology Market: Overview
3.2 Growing Market for Drug Delivery Technology and Services
3.2.1 Revenue Forecast for Overall Drug Delivery Technology Market, 2012-2017
3.2.2 Revenue Forecast for Overall Drug Delivery Market, 2018-2023
3.3 Breakdown of the Global Drug Delivery Technology Market
3.3.1 Revenue Forecast for Oral Drug Delivery Technology, 2012-2017
3.3.2 Revenue Forecast for Oral Drug Delivery Technology, 2018-2023
3.3.3 Revenue Forecast for Inhalation Drug Delivery Technology, 2012-2017
3.3.4 Revenue Forecast for Inhalation Drug Delivery Technology, 2018-2023
3.3.5 Revenue Forecast for Transdermal Drug Delivery Technology, 2012-2017
3.3.6 Revenue Forecast for Transdermal Drug Delivery Technology, 2018-2023
3.3.7 Revenue Forecast for Injectable/Implants Drug Delivery Technology, 2012-2017
3.3.8 Revenue Forecast for Injectable/Implants Drug Delivery Technology, 2018-2023
3.3.9 Revenue Forecast for Ocular Drug Delivery Technology, 2012-2017
3.3.10 Revenue Forecast for Ocular Drug Delivery Technology, 2018-2023
3.3.11 Revenue Forecast for Nasal Drug Delivery Technology, 2012-2017
3.3.12 Revenue Forecast for Nasal Drug Delivery Technology, 2018-2023
3.4 Leading National Markets for Drug Delivery Technology
3.4.1 The US Drug Delivery Technology Market, 2013-2023
3.4.2 The Japanese Drug Delivery Technology Market, 2013-2023
3.4.3 The Leading European Drug Delivery Technology Markets, 2013-2023
3.4.4 Emerging-Economy Drug Delivery Technology Markets
3.4.5 The Chinese Drug Delivery Technology Market, 2013-2023
3.4.6 The Indian Drug Delivery Technology Market, 2013-2023
3. The World Drug Delivery Technology Market to 2023
www.visiongain.com
Contents
4.1 Therapeutic Areas Offering Growth Opportunities
4.1.1 Sales of Biologics Will Stimulate Developments in Drug Delivery
4.1.2 Leading Segments of Biological Drugs Market in 2012
4.1.3 Monoclonal Antibodies Lead the Biologics Market
4.1.3.1 Prospects for Monoclonal Antibodies and Implications for Drug Delivery
4.1.4 The Human Insulins Class Will Exhibit Strong Growth
4.1.5 Erythropoietin Products – What are the Future Prospects?
4.1.5.1 Erythropoietin Products Forecast, 2013-2023
4.1.6 The Interferons Class Will Show an Increase in Revenues from 2012-2017
4.1.6.1 Long-Term Forecast for the Interferons Class
4.1.7 Granular-Colony Stimulating Factors (G-CSF) Forecast, 2013-2023
4.1.8 Recombinant Coagulation Factors Will Show Steady Growth
4.1.9 Other Therapeutic Proteins
4.1.10 The Biosimilars Market, 2012
4.1.10.1 Forecast for the Global Biosimilars Market, 2013-2023
4.1.11 Forecast for the Vaccines Market, 2013-2023
4.2 The Drug Delivery Technology Market: Conclusions
4.2.1 A Rapidly Expanding Segment of the Global Pharma Industry
5.1 Introduction
5.2 Leading Oral Drug Delivery Companies
5.2.1 Applied Pharma Research (APR)
5.2.1.1 Overview
5.2.1.2 Therapeutic Areas and Technology
5. Prominent Companies in the Drug Delivery Technology Market
4. Drug Classes That Can Benefit from Advances in Drug Delivery
www.visiongain.com
Contents 5.2.1.3 MonoSol Rx Enters into Licensing Agreement with Vestiq Pharmaceuticals for
Zuplenz
5.2.2 Catalent Pharma Solutions
5.2.2.1 Overview
5.2.2.2 Catalent's Oral Drug Delivery Technology
5.2.2.3 Catalent's Customer Base
5.2.2.4 Manufacturing Capabilities
5.2.2.5 Revenues
5.2.2.6 Catalent Pharma Acquires Clinical Trial Supplies Business
5.2.2.7 Catalent’s Actions and Progress in 2012
5.2.3 Emisphere Technologies
5.2.3.1 Overview
5.2.3.2 Emisphere's Eligen Technology
5.2.3.3 Emisphere's Pipeline Products
5.2.3.4 Emisphere's Partnered Programmes
5.2.3.5 Revenues
5.2.3.6 Future Outlook
5.2.4 Ethypharm
5.2.4.1 Overview
5.2.4.2 Ethypharm's Proprietary Technologies
5.2.4.3 Products on the Market
5.2.4.4 Development Pipeline
5.2.5 Aptalis
5.2.5.1 Overview
5.2.5.2 Aptalis's Drug Delivery Platforms
5.2.5.3 Products for Out-Licensing
5.2.5.4 Revenue
5.2.5.5 Future Outlook
5.2.6 Glycologic
5.2.6.1 Overview
www.visiongain.com
Contents 5.2.6.2 Glycologic Technology Platform
5.2.6.3 Pipeline Products
5.2.6.4 Future Outlook
5.3 Inhaled Drug Delivery
5.3.1 3M Drug Delivery Systems
5.3.1.1 Overview
5.3.1.2 Protein and Peptide Delivery
5.3.1.3 Excipient Technology for CFC-Free Inhalers
5.3.1.4 Actuator Technology for MDIs
5.3.1.5 Particle Engineering Technology
5.3.1.6 Revenues
5.3.2 Aradigm Corp.
5.3.2.1Overview
5.3.2.2 AERx Drug Delivery System
5.3.2.3 Collaborations
5.3.2.4 Pipeline Products
5.3.2.5 Revenues
5.3.3 Vectura Group
5.3.3.1 Overview
5.3.3.2 Proprietary Technologies
5.3.3.3 Pipeline Products
5.3.3.4 Revenues
5.4 Injectable Drug Delivery
5.4.1 Alkermes
5.4.1.1Overview
5.4.1.2 Proprietary Technology Platforms
5.4.1.3 Product Pipeline
5.4.1.4 Revenues
5.4.2 Pacira Pharmaceuticals
5.4.2.1 Overview
www.visiongain.com
Contents 5.4.2.2 Injectable Sustained-Release Technology
5.4.2.3 Products
5.4.2.4 Pipeline
5.4.2.5 Revenues
5.4.2.6 Future Outlook
5.4.3 Antares Pharma
5.4.3.1 Overview
5.4.3.2 Technology
5.4.3.2.1 Pressure Assisted Injection Devices
5.4.3.2.2 Transdermal Gel System
5.4.3.3 Products
5.4.3.3.1 Vision
5.4.3.3.2 Vibex
5.4.3.3.3 Pen Injector
5.4.3.4 Pipeline Technologies
5.4.3.4.1 Vibex MTX
5.4.3.5 Manufacturing
5.4.3.6 Revenues
5.4.3.7 Future Outlook
5.4.4 Bioject Medical Technologies
5.4.4.1 Technology
5.4.4.2 Products
5.4.4.2.1 Biojector 2000
5.4.4.2.2 Vitajet
5.4.4.2.3 ZetaJet
5.4.4.3 Pipeline Technologies
5.4.4.3.1 Intradermal Pen Injector
5.4.4.3.2 Iject
5.4.4.3.3 Jupiter Jet
5.4.4.4 Manufacturing
www.visiongain.com
Contents 5.4.4.5 Collaborations
5.4.4.5.1 MPI Research
5.4.4.5.2 World Health Organization (WHO)
5.4.4.6 Revenues
5.5 Transdermal Drug Delivery
5.5.1 3M
5.5.1.1 Overview
5.5.1.2 Transdermal Systems
5.5.2 Altea Therapeutics
5.5.2.1 Overview
5.5.2.2 Altea's PassPort Technology Platform
5.5.2.3 Therapeutic Focus
5.5.2.4 Nitto Denko Acquires Altea Therapeutics Assets
5.5.3 Intercell
5.5.3.1 Overview
5.5.3.2 Vaccine Patch Technology Platform
5.5.3.3 Intercell's Strategic Alliances
5.5.3.4 Revenues
5.5.3.5 Future Outlook
5.5.4 NanoPass Technologies
5.5.4.1 Overview
5.5.4.2 Technology Platform
5.5.4.3 The MicronJet Needle
5.5.4.4 NanoCare
5.5.5 Noven Pharmaceuticals
5.5.5.1 Overview
5.5.5.2 Key Products
5.5.5.3 Transdermal Pipeline
5.5.5.4 Revenues
5.6 Transmucosal Drug Delivery
www.visiongain.com
Contents 5.6.1 Overview of Technology
5.6.2 Cima Labs (Cephalon)
5.6.2.1 Overview
5.6.2.2 Cima's Transmucosal Drug Delivery Technologies
5.6.2.3 Products
5.6.3 Columbia Laboratories
5.6.3.1 Overview
5.6.3.2 Bioadhesive Delivery Technology
5.6.3.3 Products
5.6.3.4 Revenue
5.6.3.5 Future Outlook
5.6.4 Generex Biotechnology Corporation
5.6.4.1 Overview
5.6.4.2 Products
5.6.4.3 Pipeline Products
5.6.4.4 Revenue
5.7 Implant Technology
5.7.1 Overview of Technology
5.7.2 pSivida Corp.
5.7.2.1 Overview
5.7.2.2 Technologies and Products
5.7.2.2.1 Durasert Technology System
5.7.2.2.2 BioSilicon Technology System
5.7.2.2.3 CODRUG Technology System
5.7.2.3 Products
5.7.2.3.1 Iluvian Approved in Europe
5.7.2.4 Revenues
www.visiongain.com
Contents
6.1 Analysis of Strengths, Weaknesses, Opportunities and Threats (SWOT)
6.2 Patent Expiry Will Drive Biological Drug Delivery
6.2.1 Biosimilars Legislation Encourages Innovation
6.2.2 As Patents Expire, Competition Will Increase
6.3 Competitive and Lucrative Monoclonal Antibody Market Will Drive Sales
6.4 Biological Drug Delivery Technology is Already Established
6.4.1 Pegylation Has Imparted Benefits
6.4.2 New Delivery Methods for Insulin?
6.4.3 Nanotechnology Can Benefit Biological Drug Delivery
6.5 Will Regulatory Authorities Hold Back the Market?
6.5.1 Risk-Conscious FDA and EMA Will Make Approval Difficult?
6.5.2 Choice between New Technology or a New Drug? Is a Rethink Needed?
6.6 New Delivery Methods for Biologicals Must be Cost Effective and Appropriate
6.7 Injection is Still the Major Form of Delivery
6.8 Next-Generation Drugs May Limit Drug Delivery Revenues
6.8.1 Lifecycle Management via Protein Engineering Blurs Drug Delivery Lines
6.8.2 New Chemical Entities Could Restrict Biotech Growth
6.9 The Biological Drug Delivery Market Offers Great Potential, But Care is Needed
7.1 Professor Sven Frøkjær, Dean, Faculty of Pharmaceutical Sciences, University of
Copenhagen, Denmark
7.1.1 Market Value for Drug Delivery Systems
7.1.2 Key Benefits for Patients
7.1.3 On Emerging Technologies
7. Research Interviews from Our Survey
6. Drivers, Restraints and Trends in Drug Delivery
www.visiongain.com
Contents 7.1.4 On Nanotechnology
7.1.5 On Different Systems
7.1.6 Main Challenges Facing the Sector
7.1.7 On Nanoparticle Systems and Drug Delivery
7.1.8 Systems on the Market
7.1.9 Diseases of Interest
7.1.10 Therapeutic Areas Offering Opportunities
7.2 Dr Bill Lambert, Ph.D., Senior Vice President, Pharmaceutical Development, Pacira
Pharmaceuticals, San Diego, CA, USA
7.2.1 On Pacira and Drug Delivery Technology
7.2.2 Liposomal Drug Delivery
7.2.3 Applications of DepoFoam Technology
7.2.4 On Pacira's Products
7.2.5 Pipeline DDT Platforms
7.2.6 On the Market for Drug Delivery Technology
7.2.7 Therapeutic Areas Offering Market Opportunities
7.2.8 Challenges Facing Drug Delivery Industry
7.2.9 Comparing DepoFoam with Other Controlled-Release Systems
7.2.10 Mode of Delivery
7.2.11 Insulin and Liposomal Drug Delivery
7.2.12 R&D and Technologies Likely to be on Market in Future
7.3 Mr David Harris, Principal Consultant at Team Consulting Limited, UK
7.3.1 Current Market Value for Drug Delivery Systems
7.3.2 On Key Unmet Needs
7.3.3 On Research Focus in the 10-15 Years
7.3.4 On Main Challenges Facing the Sector
7.3.5 On Therapeutic Areas Offering Opportunities
7.3.6 On Pipeline Developments
7.4 Dr Ronan Mac Loughlin, Scientist at Aerogen, Galway, Ireland
7.4.1 Current Market Value for Drug Delivery Systems
www.visiongain.com
Contents 7.4.2 On Aerogen and its Drug Delivery Systems
7.4.3 On Key Unmet Needs
7.4.4 On Research Focus in the Next 10-15 Years
7.4.5 On Main Challenges Facing the Sector
7.4.6 On Therapeutic Areas Offering Opportunities
7.4.7 On Pipeline Developments
7.5 Mr. John Turanin, VP and General Manager, Zogenix Technologies, CA, USA
7.5.1 On Current State of the Market
7.5.2 On Patient Awareness and Needle-free Injectable Technology
7.5.3 On JV/M&A and Zogenix
7.5.4 Zogenix’s Product Portfolio and Technology
7.5.5 On Competing Technologies and Market Share
7.5.6 On Adoption of Zogenix’s Technology
7.5.7 On The Future Needle-Free Injection Devices
7.5.8 On Major Challenges Facing Needle-Free Injection Devices
7.5.9 On Future Growth in the Sector
7.6 Mr. Charles Potter, CBO, Glide Pharma, Oxford, UK
7.6.1 On Growth and Market Potential
7.6.2 On Patient Power and DTC Marketing
7.6.3 Glide SDI & Other Technologies
7.6.4 On Competition from Transdermal & Inhalation Technologies
7.6.5 Market Demand & Future Outlook
7.6.6 On Future Technology Trends
7.6.7 On Future Market Potential
7.7 Ms. Heather Potters, Chairman, PharmaJet, Colorado, USA
7.7.1 On Needle-Free Drug Delivery Technology Market
7.7.2 On M&A and JV Strategy for Growth
7.7.3 On PharmaJet’s Leading Products
7.7.4 On Equivalence of Fractional and Full Dose Delivery
7.7.5 Patient Awareness About Jet Injectors
www.visiongain.com
Contents 7.7.6 Unmet Needs in the Jet Injectors Market
7.7.7 Major Challenges Faced by Jet Injectors Market
7.7.8 The Outlook for Needle-Free Technology Market
8.1 The Market Shows Potential for Strong Revenue Growth
8.2 Commercial Drivers for Drug Delivery Technology
8.3 Prominent Companies in the Market
8.4 Future Outlook and Concluding Remarks
8. Conclusions of Our Research and Analyses
www.visiongain.com
Contents
Table 2.1 Top 10 Biotech Drugs, 2012
Table 2.2 Top 10 Biopharma Companies: Revenues & R&D Expenditure, 2011
Table 2.3 Amino Acid Changes for Human Insulin Analogues
Table 3.1 Drug Delivery Technology Market: World Revenues, 2012-2017
Table 3.2 Drug Delivery Technology Market: World Revenues, 2018-2023
Table 3.3 Oral Drug Delivery Technology Market: World Revenues, 2012-2017
Table 3.4 Oral Drug Delivery Technology Market: World Revenues, 2018-2023
Table 3.5 Inhalation Drug Delivery Technology Market: World Revenues, 2012-2017
Table 3.6 Inhalation Drug Delivery Technology Market: World Revenues, 2018-2023
Table 3.7 Transdermal DDT Market: World Revenues, 2012-2017
Table 3.8 Transdermal DDT Market: World Revenues, 2018-2023
Table 3.9 Injectable/Implants DDT Market: World Revenues, 2012-2017
Table 3.10 Injectable/Implants DDT Market: World Revenues, 2018-2023
Table 3.11 Ocular Drug Delivery Technology Market: World Revenues, 2012-2017
Table 3.12 Ocular Drug Delivery Technology Market: World Revenues, 2018-2023
Table 3.13 Nasal Drug Delivery Technology Market: World Revenues, 2012-2017
Table 3.14 Nasal Drug Delivery Technology Market: World Revenues, 2018-2023
Table 3.15 Drug Delivery Technology Submarkets: World Revenues, 2012-2017
Table 3.16 Drug Delivery Technology Submarkets: World Revenues, 2018-2023
Table 3.17 Drug Delivery Technology: Leading National Market Forecasts, 2012-2023
Table 4.1 Leading Drug Classes Driving the Drug Delivery Technology Market, 2011 and 2012
Table 4.2 Some Leading Monoclonal Antibody Drugs, 2013
Table 4.3 Monoclonal Antibodies Market: World Sales Forecast, 2012-2017
Table 4.4 Monoclonal Antibodies Market: World Sales Forecast, 2018-2023
Table 4.5 Insulins Market: World Sales Forecast, 2012-2017
Table 4.6 Insulins Market: World Sales Forecast, 2018-2023
List of Tables
www.visiongain.com
Contents Table 4.7 Erythropoietins Market: World Sales Forecast, 2012-2017
Table 4.8 Erythropoietins Market: World Sales Forecast, 2018-2023
Table 4.9 Some Interferon Drugs, 2013
Table 4.10 Interferons Market: World Sales Forecast, 2012-2017
Table 4.11 Interferons Market: World Sales Forecast, 2018-2023
Table 4.12 G-CSF Market: World Sales Forecast, 2012-2017
Table 4.13 G-CSF Market: World Sales Forecast, 2018-2023
Table 4.14 Some Recombinant Coagulation Factors, 2013
Table 4.15 Recombinant Coagulation Factors Market: World Sales Forecast, 2012-2017
Table 4.16 Recombinant Coagulation Factors Market: World Sales Forecast, 2018-2023
Table 4.17 Some Human Growth Hormones, 2013
Table 4.18 Some Immunosuppressant Products, 2013
Table 4.19 Other Therapeutic Proteins Market: World Sales Forecast, 2012-2017
Table 4.20 Other Therapeutic Proteins Market: World Sales Forecast, 2018-2023
Table 4.21 Some Biosimilar Drugs, 2013
Table 4.22 Biosimilars Market: World Sales Forecast, 2012-2017
Table 4.23 Biosimilars Market: World Sales Forecast, 2018-2023
Table 4.24 Some Vaccines Products, 2013
Table 4.25 Vaccines Market: World Sales Forecast, 2012-2017
Table 4.26 Vaccines Market: World Sales Forecast, 2018-2023
Table 5.1 Aradigm's Product Pipeline, 2013
Table 5.2 Alkermes' Product Pipeline, 2013
Table 5.3 Antares Pharma Licensing Partnerships, 2013
Table 5.4 Antares Pharma: Summary of Technology, 2013
Table 5.5 Bioject: Summary of Technologies, 2013
Table 5.6 Intercell's Strategic Alliances, 2013
Table 5.7 Noven's Marketed & Pipeline Transdermal Products, 2013
Table 6.1 SWOT Analysis of the Drug Delivery Industry and Market, 2013
Table 6.2 Some Leading Drugs Expected to Lose Patent Protection, 2012-2015
Table 6.3 Monoclonal Antibody Therapies Approved by the US FDA, 1986-2003
www.visiongain.com
Contents Table 6.4 Monoclonal Antibody Therapies Approved by the US FDA, 2004-2010
Table 6.5 Leading Biologic Drug Types, 2012
Table 8.1 Drug Delivery Technology Market: World Revenues, 2012, 2013, 2017, 2019, 2021 &
2023
www.visiongain.com
Contents
Figure 3.1 Drug Delivery Technology Market: World Revenues, 2012-2017
Figure 3.2 Drug Delivery Technology Market: World Revenues, 2018-2023
Figure 3.3 Oral Drug Delivery Technology Market: World Revenues, 2012-2017
Figure 3.4 Oral Drug Delivery Technology Market: World Revenues, 2018-2023
Figure 3.5 Inhalation DDT Market: World Revenues, 2012-2017
Figure 3.6 Inhalation DDT Market: World Revenues, 2018-2023
Figure 3.7 Transdermal DDT Market: World Revenues, 2012-2017
Figure 3.8 Transdermal DDT Market: World Revenues, 2018-2023
Figure 3.9 Injectable/Implants DDT Market: World Revenues, 2012-2017
Figure 3.10 Injectable/Implants DDT Market: World Revenues, 2018-2023
Figure 3.11 Ocular Drug Delivery Technology Market: World Revenues, 2012-2017
Figure 3.12 Ocular Drug Delivery Technology Market: World Revenues, 2018-2023
Figure 3.13 Nasal Drug Delivery Technology Market: World Revenues, 2012-2017
Figure 3.14 Nasal Drug Delivery Technology Market: World Revenues, 2018-2023
Figure 3.15 Drug Delivery Technology Submarkets: World Revenues, 2012-2023
Figure 3.16 US DDT Market: Sales Forecast, 2012-2023
Figure 3.17 Other Leading DDT National Markets: Sales Forecasts, 2012-2023
Figure 3.18 DDT Sales Shares in Leading National Markets, 2012
Figure 3.19 DDT Sales Shares in Leading National Markets, 2016
Figure 3.20 DDT Sales Shares in Leading National Markets, 2020
Figure 3.21 DDT Sales Shares in Leading National Markets, 2023
Figure 4.1 Monoclonal Antibodies Market: World Sales Forecast, 2012-2023
Figure 4.2 Insulins Market: World Sales Forecast, 2012-2023
Figure 4.3 Erythropoietins Market: World Sales Forecast, 2012-2023
Figure 4.4 Interferons Market: World Sales Forecast, 2012-2023
Figure 4.5 G-CSF Market: World Sales Forecast, 2012-2023
List of Figures
www.visiongain.com
Contents Figure 4.6 Recombinant Coagulation Factors Market: World Sales Forecast, 2012-2023
Figure 4.7 Other Therapeutic Proteins Market: World Sales Forecast, 2012-2023
Figure 4.8 Biosimilars Market: World Sales Forecast, 2012-2023
Figure 4.9 Vaccines Market: World Sales Forecast, 2012-2023
Figure 6.1 Different Approaches to Biological Drug Delivery, 2013
Figure 8.1 Drug Delivery Technology Market: World Revenues by Category, 2012, 2013, 2017,
2019, 2021 and 2023
Figure 8.2 Drug Delivery Technology Market: World Revenues, 2011, 2012, 2016, 2018, 2020 &
2023
Figure 8.3 Drug Delivery Technology Market: World Revenue Shares by Category, 2012
www.visiongain.com
Contents
3M
Abbott Laboratories
Actelion Pharmaceuticals
Aeras
Aerogen
Alexion Pharmaceuticals
Alimera Sciences
Alkermes
Alpha M.O.S.
Altea Therapeutics
Alvogen
Amgen
Amylin Pharmaceuticals
Antares Pharma
Antigen Express Inc
Apotex Corp
Applied Pharma Research (APR)
Aptalis Pharma
Aptuit
Aradigm Corp
Arakis
Ascend Therapeutics
AstraZeneca
Axcan Intermediate Holdings (now Aptalis Pharma)
Battelle Memorial Institute
Bausch & Lomb
Organisations Mentioned in This Report
www.visiongain.com
Contents Baxter International
Bayer
Berna Biotech
Biocon
Biogen Idec
Bioject Medical Technologies
Biological E. Limited
Biotechpharma
Boehringer Ingelheim
Bristol-Myers Squibb
Cardinal Health
Catalent Pharma Solutions
Celgene Corporation
Cell Therapeutics
Cephalon
Chiron Corporation
Cima Labs (Cephalon)
Circassia
Columbia Laboratories
CSL Limited
CT Arzneimittel
Dendreon Corp.
Dr. Reddy's Laboratories
EKR Therapeutics
Elan Pharmaceuticals
Eli Lilly and Company
Elite Pharmaceuticals
Emisphere Technologies
Endo Pharmaceuticals
Ethypharm
www.visiongain.com
Contents Eurand Pharmaceuticals
Eurofarma
European Medicines Agency (EMA)
Ferring Pharmaceuticals
Flynn Pharma
Food and Drug Administration (US FDA)
Fresenius Group
Genentech (now part of Roche)
Generex Biotechnology Corporation
geneRx+
GeneScience Pharmaceuticals
Genmab
Genta
Genzyme Corporation
Gilead Sciences
GlaxoSmithKline (GSK)
Glide Pharma
Glycologic Limited
Hisamitsu Pharmaceutical Co.
Intercell
Janssen Biotech
Johnson & Johnson Services (J&J)
Labtec
Leiras OY (Nycomed)
LG Life Sciences
MannKind Corporation
Massachusetts Institute of Technology (MIT)
Medicines and Healthcare products Regulatory Agency (MHRA)
Merck & Co
Merck Serono
www.visiongain.com
Contents Minnesota Rubber and Plastics (MRP)
MonoSol Rx
MPI Research
MundiPharma
Mylan
NanoPass Technologies
National Institute for Health and Clinical Excellence (NICE, UK)
National Institute of Health (NIH, USA)
Nektar Therapeutics
Nordic Bioscience
Novartis Pharma
Noven Pharmaceuticals
Novo Nordisk
Novogyne Pharmaceuticals
Otsuka Pharmaceuticals Co.
Pacira Pharmaceutical
Par Pharmaceutical Companies
Pfizer
PharmaJet
Pre-clinical Partnerships
ProFibrix
pSivida Corp.
Ranbaxy Laboratories
Recipharm
Roche
Romark
Sandoz (now part of Novartis)
Sanofi (formally Sanofi-Aventis)
Schering-Plough Corporation (now part of Merck & Co.)
Shire
www.visiongain.com
Contents Sigma-Tau Pharmaceuticals
SkyePharma
Sosei Group Corp.
Spectrum Pharmaceuticals
Statens Serum Institut
Strativa Pharmaceuticals
Takeda Pharmaceutical Company
Team Consulting Ltd
Teva Pharmaceuticals Industries
The Blackstone Group
The United Nations Children's Fund (UNICEF)
TRION Pharma
UCB
University of Copenhagen, Denmark
US Department of Health and Human Services
Vectura Group
Vestiq Pharmaceuticals
Whitehall Laboratories
World Health Organization (WHO)
Wyeth (now a part of Pfizer Inc.)
Zhejiang CONBA Pharmaceutical Co.
Zogenix Technologies
Page 78
www.visiongain.com
Drug Delivery Technologies: Commercial Prospects 2013-2023
Visiongain believes that this class will show steady, low single-digit growth throughout the forecast
period, 2013 to 2023. Revenues will increase to $5.67bn in 2017 and $6.04bn in 2023 (Tables
4.15-4.16 and Figure 4.6). The initial growth of sales in this class will be due to steady increases in
sales of the current leading drugs. The introduction of new drugs will also contribute to growth of
this class, our analyses reveal. That product category will be a main revenue growth driver for drug
delivery technologies – products and services.
Source: visiongain 2013
Generic Name Brand Name CompanyEptacog alfa/ recombinant human coagulation Factor VIIa (rFVIIa) NovoSeven Novo Nordisk
Factor VIII Recombinate Baxter International
Factor VIII (procoagulant) Advate Baxter InternationalOctocog alfa Kogenate FS Bayer HealthCare
Factor VIII/ von Willebrand Factor Complex Humate P CSL BehringOctocog alfa Helixate FS CSL Behring
Factor VIII Xyntha Pfizer
Factor IX BeneFIX Pfizer
Factor VIII Koate-DVI Talecris Biotherapeutics
Factor VIII Monoclate-P CSL Behring
Factor VIII ReFacto PfizerFactor IX Mononine CSL Behring
Table 4.14 Some Recombinant Coagulation Factors, 2013
Table 4.15 Recombinant Coagulation Factors Market: World Sales Forecast, 2012-2017
2012 2013 2014 2015 2016 2017Recombinant Coagulation Factors ($bn) 5.13 5.36 5.47 5.55 5.63 5.67Annual Growth (%) 6 4 2 1 2 1CAGR (%) 2.0
Source: visiongain 2013; CAGR values are for 2012-2017
Page 79
www.visiongain.com
Drug Delivery Technologies: Commercial Prospects 2013-2023
4.1.9 Other Therapeutic Proteins Other categories of therapeutic proteins include the following:
Human growth hormones
Immunosuppressant proteins
Enzyme replacements
Follicle stimulating hormones.
Some of the leading products in this category are available as lyophilised powder formulations that
require reconstitution before use. Many of the leading growth hormones are available in prefilled
Source: visiongain 2013
2018 2019 2020 2021 2022 2023Recombinant Coagulation Factors ($bn) 5.74 5.80 5.85 5.89 5.92 6.04Annual Growth (%) 1 1 1 1 1 2CAGR (%) 1.0
Table 4.16 Recombinant Coagulation Factors Market: World Sales Forecast, 2018-2023
Figure 4.6 Recombinant Coagulation Factors Market: World Sales Forecast, 2012-2023
Source: visiongain 2013; CAGR values are for 2018-2023
5.1
5.4 5.5
5.5 5.6
5.7
5.7
5.8
5.9
5.9
5.9
6.0
4.6
4.8
5.0
5.2
5.4
5.6
5.8
6.0
6.2
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Sale
s ($
bn)
Year